Published in Immunobiology on June 17, 2012
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (RACE) | NCT01157065
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood (2014) 1.55
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol (2012) 1.30
Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J Immunol (2014) 1.25
Progress and Trends in Complement Therapeutics. Adv Exp Med Biol (2013) 1.20
Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov (2015) 1.16
Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol (2014) 1.15
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest (2015) 1.08
Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol (2013) 1.07
Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol (2014) 0.94
Therapeutic control of complement activation at the level of the central component C3. Immunobiology (2015) 0.94
Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology (2012) 0.93
Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology (2012) 0.93
Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology (2014) 0.91
Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology (2015) 0.90
Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. FASEB J (2013) 0.89
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther (2015) 0.87
Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87
Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. Innate Immun (2013) 0.86
A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis. Mol Ther (2013) 0.85
Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. Horm Metab Res (2014) 0.84
Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. Exp Eye Res (2013) 0.83
The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin Exp Immunol (2015) 0.82
Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol (2016) 0.82
Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol (2016) 0.81
New milestones ahead in complement-targeted therapy. Semin Immunol (2016) 0.81
Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol (2015) 0.80
From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology (2016) 0.80
Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. ChemMedChem (2014) 0.79
Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches. Adv Exp Med Biol (2015) 0.79
Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev (2016) 0.78
Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clin Immunol (2015) 0.78
Inflammaging in skin and other tissues - the roles of complement system and macrophage. Inflamm Allergy Drug Targets (2014) 0.77
C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clin Exp Immunol (2013) 0.77
New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics. J Med Chem (2014) 0.76
Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex. J Infect Dis (2016) 0.76
Targeting the complement cascade: novel treatments coming down the pike. Kidney Int (2016) 0.75
Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. J Chromatogr B Analyt Technol Biomed Life Sci (2016) 0.75
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Mol Ther Oncolytics (2016) 0.75
Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics. J Immunol (2017) 0.75
Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clin Immunol (2016) 0.75
Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol (2017) 0.75
Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood. Xenotransplantation (2016) 0.75
Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes. J Immunol (2017) 0.75
Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. Acta Biomater (2017) 0.75
Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Front Immunol (2017) 0.75
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology (2017) 0.75
Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev (2017) 0.75
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem (2006) 1.72
Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem (2007) 1.71
Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood (2010) 1.56
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol (2000) 1.44
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood (2010) 1.44
Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem (2005) 1.28
Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A (2005) 1.28
Recent developments in low molecular weight complement inhibitors. Mol Immunol (2009) 1.23
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol (2010) 1.18
The medicinal chemistry of peptides. Curr Med Chem (2009) 1.15
Solution structure of Compstatin, a potent complement inhibitor. Protein Sci (1998) 1.15
Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures. Semin Ophthalmol (2011) 1.13
Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol (2003) 1.12
New compstatin variants through two de novo protein design frameworks. Biophys J (2010) 1.08
Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol (2010) 1.00
Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit (2009) 0.99
Therapeutic complement inhibition: new developments. Semin Thromb Hemost (2010) 0.99
Taking complement to the clinic--has the time finally come? Scand J Immunol (2009) 0.95
Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chem Biol (2011) 0.94
A new generation of potent complement inhibitors of the Compstatin family. Chem Biol Drug Des (2011) 0.91
Synthesis of N-methylated cyclic peptides. Nat Protoc (2012) 0.90
Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers (2008) 0.89
Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci (2008) 0.86
In vitro ADMET and physicochemical investigations of poly-N-methylated peptides designed to inhibit Abeta aggregation. Bioorg Med Chem (2010) 0.84
Insulin glargine: the first clinically useful extended-action insulin analogue. Expert Opin Pharmacother (2001) 0.82
Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration. Nat Rev Drug Discov (2009) 0.81
Oostatic peptides containing D-amino acids: synthesis, oostatic activity, degradation, accumulation in ovaries and NMR study. Amino Acids (2011) 0.78
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab (2007) 6.91
Extracellular histones are major mediators of death in sepsis. Nat Med (2009) 6.55
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe (2011) 5.06
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24
Structure of C3b reveals conformational changes that underlie complement activity. Nature (2006) 3.22
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Progenitors of interstitial cells of cajal in the postnatal murine stomach. Gastroenterology (2008) 2.85
Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2002) 2.83
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood (2007) 2.72
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood (2002) 2.62
The genome of the pear (Pyrus bretschneideri Rehd.). Genome Res (2012) 2.55
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol (2009) 2.54
The IRE1alpha-XBP1 pathway of the unfolded protein response is required for adipogenesis. Cell Metab (2009) 2.52
Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 2.48
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med (2003) 2.38
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology (2006) 2.26
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology (2005) 2.18
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med (2005) 2.09
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Structural basis for complement factor H linked age-related macular degeneration. J Exp Med (2007) 2.02
Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol (2011) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 1.98
The pluripotency rheostat Nanog functions as a dimer. Biochem J (2008) 1.97
The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One (2011) 1.96
A structural basis for complement inhibition by Staphylococcus aureus. Nat Immunol (2007) 1.95
P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. Chem Rev (2010) 1.95
Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci U S A (2010) 1.91
Microbial hijacking of complement-toll-like receptor crosstalk. Sci Signal (2010) 1.91
A conformational switch in vinculin drives formation and dynamics of a talin-vinculin complex at focal adhesions. J Biol Chem (2006) 1.90
A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 1.89
Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. J Clin Invest (2012) 1.87
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol (2003) 1.84
Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol (2010) 1.83
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Two distinct head-tail interfaces cooperate to suppress activation of vinculin by talin. J Biol Chem (2005) 1.79
Analysis of oral microbiota in children with dental caries by PCR-DGGE and barcoded pyrosequencing. Microb Ecol (2010) 1.77
Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol (2004) 1.74
The immune protein CD3zeta is required for normal development of neural circuits in the retina. Neuron (2010) 1.74
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem (2006) 1.72
Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem (2007) 1.71
7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. Proc Natl Acad Sci U S A (2009) 1.71
Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci U S A (2007) 1.71
Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol (2008) 1.70
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood (2003) 1.68
A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. J Am Chem Soc (2008) 1.67
Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin-mediated cell-cell contacts. J Exp Med (2006) 1.67
The role of complement in biomaterial-induced inflammation. Mol Immunol (2006) 1.67
Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66
Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 1.65
Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes (2008) 1.65
The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol (2010) 1.64
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. J Cell Biol (2004) 1.63
Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol (2006) 1.63
Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature (2013) 1.61
Methamphetamine enhances HIV infection of macrophages. Am J Pathol (2008) 1.60
Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science (2010) 1.59
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. Circ Res (2010) 1.56
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood (2010) 1.56